Prostate Cancer | Specialty

Key Updates: Bone-Targeted Therapy for Metastatic CRPC

November 27th 2018

Bone Health in Prostate Cancer

November 27th 2018

Biochemical Prostate Cancer Recurrence Post Surgery/RT

November 27th 2018

Nonmetastatic CRPC: Does It Exist?

November 27th 2018

Defining Disease Volume in Metastatic Prostate Cancer

November 27th 2018

Radiotherapy for Oligometastatic Prostate Cancer

November 27th 2018

M0 Stage Prostate Cancer

November 27th 2018

Dose-Escalation Strategy Feasible With Novel Radionuclide Treatment in mCRPC

November 21st 2018

Scott T. Tagawa, MD, discusses an emerging treatment modality for patients with progressive metastatic castration-resistant prostate cancer.

Surgery and Adjuvant RT Show Superiority in Locally Advanced Prostate Cancer

November 20th 2018

Higher survival rates were observed with radical prostatectomy and adjuvant radiotherapy compared with radiotherapy and androgen deprivation therapy in men with locally advanced prostate cancer.

Hypofractionated Radiation Recommended for Localized Prostate Cancer

November 20th 2018

A panel of experts has recommended hypofractionated radiation as an alternative to longer, conventional courses of radiation for men with earlystage prostate cancer who opt for external beam radiation therapy.

Dr. Morris Discusses PSMA-Targeted Imaging in mCRPC

November 20th 2018

Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the use of prostate-specific membrane antigen (PSMA)-targeted imaging in patients with metastatic castration-resistant prostate cancer.

EU Panel Backs Apalutamide in Nonmetastatic CRPC

November 19th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use granted support for approval of apalutamide for the treatment of adult patients with nonmetastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease.

Dr. Bradley on Exercise in Treatment-Related AE Management

November 16th 2018

Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the importance of exercise in the management of prostate cancer treatment-related adverse events.

Dr. Parker on the Rationale for Radiotherapy in Metastatic Prostate Cancer

November 14th 2018

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the rationale for radiotherapy in the treatment of newly-diagnosed metastatic prostate cancer.

New Approaches to Localized Prostate Cancer Combat Overtreatment

November 14th 2018

Mark Emberton, MD, FRCS, discusses updates in the diagnosis and treatment of patients with localized prostate cancer.

Expert Explains Surgical Considerations in High-Risk Prostate Cancer

November 13th 2018

James Kearns, MD, discusses key issues to consider with surgery in patients with high-risk prostate cancer.

Dr. Emberton Addresses Issues in Diagnosing Localized Prostate Cancer

November 10th 2018

Mark Emberton, MD, FRCS, professor, Interventional Oncology, Division of Surgery and Interventional Science, University College London, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, addresses issues in the diagnosis of localized prostate cancer.

Dr. Tagawa Discusses Radiotherapy in Prostate Cancer

November 8th 2018

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses radiotherapy in the treatment of patients with prostate cancer.

Dr. Burgess on Immunotherapy in Prostate Cancer

November 1st 2018

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, discusses the role of immunotherapy in prostate cancer.

Burgess Shares Insight on Evolving Prostate Cancer Paradigm

October 31st 2018

Earle Burgess, MD, discusses the shifting paradigm of metastatic castration-sensitive prostate cancer.